These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12445426)

  • 21. Steatosis affects chronic hepatitis C progression in a genotype specific way.
    Rubbia-Brandt L; Fabris P; Paganin S; Leandro G; Male PJ; Giostra E; Carlotto A; Bozzola L; Smedile A; Negro F
    Gut; 2004 Mar; 53(3):406-12. PubMed ID: 14960525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship between serum adiponectin and steatosis in patients with chronic hepatitis C genotype-4.
    Ashour E; Samy N; Sayed M; Imam A
    Clin Lab; 2010; 56(3-4):103-10. PubMed ID: 20476641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.
    Poynard T; Bedossa P; Opolon P
    Lancet; 1997 Mar; 349(9055):825-32. PubMed ID: 9121257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C.
    Fartoux L; Poujol-Robert A; Guéchot J; Wendum D; Poupon R; Serfaty L
    Gut; 2005 Jul; 54(7):1003-8. PubMed ID: 15951550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin resistance: a major factor associated with significant liver fibrosis in Egyptian patients with genotype 4 chronic hepatitis C.
    El Ray A; Asselah T; Moucari R; El Ghannam M; Taha AA; Saber MA; Akl M; Atta R; Shemis M; Radwan AS; Ghali A; Paradis V; Marcellin P
    Eur J Gastroenterol Hepatol; 2013 Apr; 25(4):421-7. PubMed ID: 23470266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients.
    Péres DP; Cheinquer H; Wolf FH; Cheinquer N; Falavigna M; Péres LD
    Ann Hepatol; 2013; 12(6):871-5. PubMed ID: 24114816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C.
    Adinolfi LE; Utili R; Andreana A; Tripodi MF; Marracino M; Gambardella M; Giordano M; Ruggiero G
    Dig Dis Sci; 2001 Aug; 46(8):1677-83. PubMed ID: 11508667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HCV liver infection and liver steatosis: evidence for indirect mechanisms in genotype 3?
    Grassi A; Ballardini G; Susca M; Bianchini F; Bonoli S; Bianchi FB; Lenzi M
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():79-82. PubMed ID: 16225480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of serum adipocytokines with insulin resistance and liver injury in patients with chronic hepatitis C genotype 4.
    Khattab MA; Eslam M; Aly MM; Shatat M; Hussen A; Moussa YI; Elsaghir G; Abdalhalim H; Aly A; Gaber S; Harrison SA
    J Clin Gastroenterol; 2012; 46(10):871-9. PubMed ID: 22664476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients.
    Adinolfi LE; Ingrosso D; Cesaro G; Cimmino A; D'Antò M; Capasso R; Zappia V; Ruggiero G
    Hepatology; 2005 May; 41(5):995-1003. PubMed ID: 15834927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.
    Rubbia-Brandt L; Quadri R; Abid K; Giostra E; Malé PJ; Mentha G; Spahr L; Zarski JP; Borisch B; Hadengue A; Negro F
    J Hepatol; 2000 Jul; 33(1):106-15. PubMed ID: 10905593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Steatosis in hepatitis C virus infection. Response to anti-viral therapy.
    Szanto P; Grigorescu M; Dumitru I; Serban A
    J Gastrointestin Liver Dis; 2006 Jun; 15(2):117-24. PubMed ID: 16802005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C.
    Fartoux L; Chazouillères O; Wendum D; Poupon R; Serfaty L
    Hepatology; 2005 Jan; 41(1):82-7. PubMed ID: 15690484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.
    Lok AS; Everhart JE; Chung RT; Padmanabhan L; Greenson JK; Shiffman ML; Everson GT; Lindsay KL; Bonkovsky HL; Di Bisceglie AM; Lee WM; Morgan TR; Ghany MG; Morishima C;
    Clin Gastroenterol Hepatol; 2007 Feb; 5(2):245-54. PubMed ID: 17296533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Steatosis in chronic hepatitis C: relationship to the virus and host risk factors.
    Matos CA; Perez RM; Pacheco MS; Figueiredo-Mendes CG; Lopes-Neto E; Oliveira EB; Lanzoni VP; Silva AE; Ferraz ML
    J Gastroenterol Hepatol; 2006 Aug; 21(8):1236-9. PubMed ID: 16872303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease.
    Abraham R; Ramakrishna B; Balekuduru A; Daniel HD; Abraham P; Eapen CE; Kurian G
    Indian J Gastroenterol; 2009; 28(2):53-8. PubMed ID: 19696989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin.
    Guedj H; Guedj J; Negro F; Lagging M; Westin J; Bochud PY; Bibert S; Neumann AU;
    J Viral Hepat; 2012 Jul; 19(7):488-96. PubMed ID: 22676361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3.
    Borghi V; Puoti M; Mussini C; Bellelli S; Angeletti C; Sabbatini F; Prati F; Cossarizza A; Esposito R
    Antivir Ther; 2008; 13(8):1057-65. PubMed ID: 19195331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histological features of chronic hepatitis C in haemodialysis patients.
    Sakellariou S; Boletis JN; Sypsa V; Psichogiou M; Tiniakos D; Delladetsima I
    Liver Int; 2014 Jul; 34(6):e56-61. PubMed ID: 25234282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hepatitis C virus-associated and metabolic steatosis. Different or overlapping diseases?].
    Lonardo A; Loria P; Adinolfi LE; Andreana A; Ruggiero G; Carulli N
    Ann Ital Med Int; 2005; 20(1):10-22. PubMed ID: 15859390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.